The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue

International Journal of Laboratory Hematology

Volumn 39, Issue , 2017, Pages 37-40

  Adcock, D M ^a   Gosselin, R C ^b  

^a LABORATORY CORPORATION OF AMERICA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

activated partial thromboplastin time; direct oral anticoagulants; prothrombin time; risk; safety

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; AWARENESS; CORRELATIONAL STUDY; DRUG MECHANISM; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PATIENT HARM; PATIENT SAFETY; PROTHROMBIN TIME; REVIEW; VEIN THROMBOSIS; DRUG MONITORING; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

EID: 85018721004     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12658     Document Type: Review

References (20)

1. Olaiya A, Lurie B, Watt B, et al. An observational study of the direct oral anticoagulant awareness indicating inadequate recognition with potential for patient harm. J Thromb Haemost. 2016;14:987-990.
2. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. Am J Med. 2015;128:1300-1305.
3. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants (DOACs): a systematic review. Chest. 2016;151:127-138. doi: 10.1016/j.chest.2016.08.1462
4. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419s-e494s.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
6. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
7. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
8. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
9. Adcock DM, Gosselin RC. Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res. 2015;136:7-12.
10. Adcock DM, Brien WF, Duff SL, et al. Procedures for the Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline. CLSI document H54-A. 2005. Wayne, PA: Clinical and Laboratory Standards Institute.
11. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral direct Xa inhibitor. Thromb Haemost. 2010;103:815-825.
12. Tripodi A, Chantarngkul V, Guinet C, et al. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost. 2011;9:226-228.
13. Weitz JI. Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res. 2011;127(Suppl 2):S5-S12.
14. Smythe MA, Priziola J, Dobesh PP, et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;14:165-186.
15. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006;296:935-942.
16. Haas S. Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost. 2010;103:686-688.
17. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38:505-513.
18. Baglin T. The measurement and application of thrombin generation. Br J Haematol. 2005;130:653-661.
19. Francart SJ, Hawes EM, Deal AM, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014;111:1133-1140.
20. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patient on therapeutic doses of dabigatran: a cross-sectional pharmacodynamics study based on peak and trough plasma levels. J Thromb Haemost. 2013;11:1493-1502.